期刊
NEURO-ONCOLOGY
卷 18, 期 4, 页码 467-478出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nov179
关键词
diffusion; high-grade glioma; imaging biomarker; perfusion; physiologic imaging
资金
- Southern California Clinical and Translational Science Institute (National Institutes of Health/National Center for Research Resources/National Center for Advancing Translational Sciences) [KL2TR000131]
Aside from bidimensional measurements from conventional contrast-enhanced MRI, there are no validated or FDA-qualified imaging biomarkers for high-grade gliomas. However, advanced functional MRI techniques, including perfusion-and diffusion-weighted MRI, have demonstrated much potential for determining prognosis, predicting therapeutic response, and assessing early treatment response. They may also prove useful for differentiating pseudoprogression from true progression after temozolomide chemoradiation and pseudoresponse from true response after anti-angiogenic therapy. This review will highlight recent developments using these techniques and emphasize the need for technical standardization and validation in prospective studies in order for these methods to become incorporated into standard-of-care imaging for brain tumor patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据